Abstract:Alpha-synuclein plays a key role in the pathogenesis of Parkinson's disease (PD). A robust transgenic mouse model has been generated that overexpresses the mutant human A53T alpha-synuclein under the mouse prion protein gene promoter; these mice develop age-dependent motor deficits. Recently, compared to wild-type (WT) littermates, A53T alpha-synuclein mice were reported to display non-motor symptom deficits, e.g., anxiety-like and depressive-like behaviors, odor discrimination and detection impairments, and gastrointestinal dysfunction, at 6 months of age or older. However, the differences between heterozygous and homozygous mice in terms of non-motor symptoms and whether the genomic DNA levels of alpha-synuclein correlate with the symptoms have not yet been elucidated. In the present work, we used littermate WT and heterozygous and homozygous A53T mice that were characterized by a modified genotyping protocol and observed a unilateral decline in the dopamine transporter (DAT) distribution from 3 months to 12 months of age in homozygous mice. We evaluated non-motor symptoms by measuring colon motility, anxiety-like and depressive-like behaviors, and motor coordination. The results showed that homozygous A53T mice exhibited earlier abnormal non-motor symptoms compared to their heterozygous littermates. The severity of impaired colon motility as well as anxiety-like and depressive-like behaviors were correlated with the genomic DNA levels of A53T mutant alpha-synuclein. More noticeable, motor coordination aberrances were also observed in homozygous A53T mice. This study provides direct evidence that the genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T mouse model, indicating that the genomic DNA levels of mutant alpha-synuclein should be tightly manipulated in PD model studies.

Yeast As A Model To Study The Roles Of Aging Regulation Path Way Sip2-Sch9 In Alpha-Synuclein Pathogenesis

High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast

α-Synuclein toxicity in yeast and human cells is caused by cell cycle re-entry and autophagy degradation of ribonucleotide reductase 1

Senescence and impaired DNA damage responses in alpha-synucleinopathy models

Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy

Screening and characterization of aging regulators using synthesized yeast chromosome<i>XIII</i>

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

Neuropathology in Mice Expressing Human Alpha-Synuclein.

The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson's disease

A versatile yeast model identifies the pesticides cymoxanil and metalaxyl as risk factors for synucleinopathies

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

Causative links between ER stress and oxidative damage in a yeast model of human N88S seipinopathy

Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid-β (Aβ) Toxicity in Yeast

The Role of Alpha Synuclein in Synucleinopathy: Impact on Lipid Regulation at Mitochondria ER Membranes

Genetic background modifies phenotypic and transcriptional responses in a C. elegans model of α-synuclein toxicity

Aberrant Adenosine A(2a) Receptor Signaling Contributes To Neurodegeneration And Cognitive Impairments In A Mouse Model Of Synucleinopathy

A model of inborn metabolism errors associated with adenine amyloid-like fiber formation reduces TDP-43 aggregation and toxicity in yeast

Genomic DNA Levels of Mutant Alpha-Synuclein Correlate with Non-Motor Symptoms in an A53T Parkinson's Disease Mouse Model

Screening and characterization of aging regulators using synthesized yeast chromosome XIII

Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein